Covid Updates
$BNTX Plan to supply 900M doses of COMIRNATY to the European Commission. source
Pipeline Updates
$ASND Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile. source
$HRTX PDUFA date for HTX-011 set at May 12, 2021. source
$IMGN Mirvetuximab FORWARD II study selected to present at ASCO on June 4-8. source
$KOD Plan to initiate two pivotal Phase 3 studies and complete additional pivotal study of KSI-301 in 2021. source
$SAVA Initiates Cognition Maintenance Study to evaluate simufilam in patients with Alzheimer's disease. source
$OSMT Upneeq wins 2021 MedTech Breakthrough Award. source
$CUE Reports confirmed partial response in Phase 1 monotherapy study of CUE-101. source
$LQDA Resubmitted NDA on 5/7/21 for LIQ861 which included additional chemistry, manufacturing, and controls clarification. source
$MBIO FDA has accepted IND application to initiate Phase 1/2 study of MB-106. source
$ALXO Announces first patient dosed in Phase 2 ASPEN-03 study. source
$GTHX Initiates PRESERVE 4 Phase 2 study of COSELA. source
$EGRX Announces TREAKISYM RI has been filed with PMDA in Japan. source
$FBIO Enters into licensing agreement with Fuji Yakuhin Co. Ltd. for development of Dotinurad. source
$AUPH Phase 3 AURORA 1 study results published in The Lance. source
$CMPI Expands vidutolimod program into non-melanoma skin cancers in combo with Libtayo. source
$IDYA Announced dose expansion in Phase 1/2 Darovasertib and Crizotinib combo study. source
Financial Updates
$BNTX Plan to establish first regional headquarters for southeast Asian in Singapore. source
$DVAX Announces proposed private offering of $200M of convertible senior notes. source
$INSM Intends to offer and sell $250M of its common stock. source